Table 2. Prognostic factors-univariate analysis.
| Characteristic | Parameter | No of pts (%) | P-value | |||
|---|---|---|---|---|---|---|
| OS | RFS | LRRFS | DMFS | |||
| Age | >35 | 76(8.5%) | 0.496 | 0.455 | 0.479 | 0.365 |
| ≤35 | 822(91.5%) | |||||
| Surgery type | total | 827(92.1%) | 0.654 | 0.563 | 0.913 | 0.253 |
| partial | 58(6.5%) | |||||
| unknown | 13(1.4%) | |||||
| Axillary LN evaluation | none | 5(0.6%) | 0.991 | 0.461 | 0.937 | 0.44 |
| SLNB | 20(2.2%) | |||||
| ALNB | 846(94.2%) | |||||
| SLNB+ALNB | 16(1.8%) | |||||
| Unknown | 11(1.2%) | |||||
| Positive lymph nodes | none | 375(41.8%) | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| 1-3 | 249(27.7%) | |||||
| 4 or more | 217(24.2%) | |||||
| Unknown | 57(6.3%) | |||||
| pT stage | 1 | 272(30.3%) | <0.0001 | 0.201 | 0.014 | <0.0001 |
| 2 | 467(52.0%) | |||||
| 3 | 49(5.5%) | |||||
| 4 | 22(2.4%) | |||||
| Unknown | 88(9.8%) | |||||
| pN stage | 0 | 408(45.4%) | <0.0001 | <0.0001 | 0.002 | <0.0001 |
| 1 | 253(28.2%) | |||||
| 2 | 117(13.1%) | |||||
| 3 | 110(12.2) | |||||
| Unknown | 10(1.1%) | |||||
| LVI | Positive | 26(2.9%) | 0.042 | 0.026 | 0.084 | 0.043 |
| Negative | 872(97.1%) | |||||
| BVI | Positive | 19(2.1%) | 0.001 | 0.208 | 0.506 | 0.007 |
| Negative | 879(97.9%) | |||||
| ECE | Positive | 20(2.2%) | 0.853 | 0.26 | 0.038 | 0.622 |
| Negative | 878(97.8%) | |||||
| ER | Positive | 613(69.3%) | 0.009 | 0.6 | 0.853 | 0.418 |
| Negative | 274(30.5%) | |||||
| Unknown | 11(1.2%) | |||||
| PR | Positive | 597(66.5%) | 0.005 | 0.561 | 0.49 | 0.112 |
| Negative | 290(32.2%) | |||||
| Unknown | 11(1.3%) | |||||
| HER2 | Negative | 654(72.8%) | 0.614 | 0.059 | 0.468 | 0.717 |
| Positive | 142(15.8%) | |||||
| Unknown | 102(11.4%) | |||||
| Ki-67 | <20% | 219(24.4%) | 0.014 | 0.487 | 0.540 | 0.804 |
| ≥ 20% | 535(59.6%) | |||||
| Unknown | 144(16.0%) | |||||
| Subtype | ER/PR+HER2- | 502(55.9%) | 0.215 | 0.848 | 0.842 | 0.378 |
| ER/PR+HER2+ | 84(9.4%) | |||||
| ER/PR-HER2+ | 59(6.6%) | |||||
| Triple negative | 143(15.9%) | |||||
| Unknown | 110(12.2%) | |||||
| Histologic grade | I | 20(2.2%) | 0.079 | 0.853 | 0.745 | 0.757 |
| II | 218(24.3%) | |||||
| III | 393(43.8%) | |||||
| Unknown | 267(29.7%) | |||||
| Chemotherapy | Used | 852(94.9%) | 0.325 | 0.848 | 0.313 | 0.005 |
| Not used | 46(5.1%) | |||||
| Radiotherapy | Used | 359(40.0%) | 0.325 | 0.003 | 0.002 | 0.013 |
| Not used | 539(60.0%) | |||||
| Hormone therapy | Used | 607(67.6%) | <0.0001 | 0.11 | 0.81 | 0.007 |
| Not used | 277(30.8%) | |||||
| Unknown | 14(1.6%) | |||||
| IMPC | Positive | 170(18.9%) | 0.592 | 0.003 | 0.002 | 0.923 |
| negative | 728(81.1%) | |||||
OS: overall survival
RFS: recurrence-free survival
LRRFS: loco-regional recurrence-free survival
DMFS: distant metastasis-free survival
pT stage: pathologic T stage
pN stage: pathologic N stage
ER: estrogen receptor
PR: progestrone receptor